Literature DB >> 18179816

IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function.

Bryn H Salt1, Julie E Niemela, Rahul Pandey, Eric P Hanson, Raquel P Deering, Ralph Quinones, Ashish Jain, Jordan S Orange, Erwin W Gelfand.   

Abstract

BACKGROUND: Patients with hypomorphic nuclear factor-kappaB essential modulator (NEMO) mutations have extensive phenotypic variability that can include atypical infectious susceptibility.
OBJECTIVE: This study may provide important insight into immunologic mechanisms of host defense.
METHODS: Immunologic evaluation, including studies of Toll-like receptor (TLR) function, was performed in a 6-month-old boy with normal ectodermal development who was diagnosed with Pneumocystis pneumonia and cytomegalovirus sepsis.
RESULTS: Genomic and cDNA sequencing demonstrated a novel NEMO missense mutation, 337G->A, predicted to cause a D113N (aspartic acid to asparagine) substitution in the first coiled-coil region of the NEMO protein. Quantitative serum immunoglobulins, lymphocyte subset numbers, and mitogen-induced lymphocyte proliferation were essentially normal. The PBMC responses to TLR ligands were also surprisingly normal, whereas natural killer cell cytolytic activity, T-cell proliferative responses to specific antigens, and T-cell receptor-induced NF-kappaB activation were diminished.
CONCLUSION: Unlike the unique NEMO mutation described here, the most commonly reported mutations are clustered at the 3' end in the tenth exon, which encodes a zinc finger domain. Because specific hypomorphic variants of NEMO are associated with distinctive phenotypes, this particular NEMO mutation highlights a dispensability of the region including amino acid 113 for TLR signaling and ectodysplasin A receptor function. This region is required for certain immunoreceptor functions as demonstrated by his susceptibility to infections as well as natural killer cell and T-cell defects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18179816      PMCID: PMC3050055          DOI: 10.1016/j.jaci.2007.11.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

1.  X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling.

Authors:  R Döffinger; A Smahi; C Bessia; F Geissmann; J Feinberg; A Durandy; C Bodemer; S Kenwrick; S Dupuis-Girod; S Blanche; P Wood; S H Rabia; D J Headon; P A Overbeek; F Le Deist; S M Holland; K Belani; D S Kumararatne; A Fischer; R Shapiro; M E Conley; E Reimund; H Kalhoff; M Abinun; A Munnich; A Israël; G Courtois; J L Casanova
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

Review 2.  Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation.

Authors:  Jordan S Orange; Ofer Levy; Raif S Geha
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

3.  Novel splicing mutation in the NEMO (IKK-gamma) gene with severe immunodeficiency and heterogeneity of X-chromosome inactivation.

Authors:  Karen Helene Ørstavik; Marianne Kristiansen; Gun Peggy Knudsen; Kari Storhaug; Ashild Vege; Kristin Eiklid; Tore G Abrahamsen; Asma Smahi; Jon Steen-Johnsen
Journal:  Am J Med Genet A       Date:  2006-01-01       Impact factor: 2.802

4.  Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.

Authors:  A Jain; C A Ma; S Liu; M Brown; J Cohen; W Strober
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations.

Authors:  W M Comans-Bitter; R de Groot; R van den Beemd; H J Neijens; W C Hop; K Groeneveld; H Hooijkaas; J J van Dongen
Journal:  J Pediatr       Date:  1997-03       Impact factor: 4.406

6.  Development of a clinical assay to evaluate toll-like receptor function.

Authors:  Raquel P Deering; Jordan S Orange
Journal:  Clin Vaccine Immunol       Date:  2006-01

7.  A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).

Authors:  J Zonana; M E Elder; L C Schneider; S J Orlow; C Moss; M Golabi; S K Shapira; P A Farndon; D W Wara; S A Emmal; B M Ferguson
Journal:  Am J Hum Genet       Date:  2000-10-24       Impact factor: 11.025

8.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

Authors:  M J May; F D'Acquisto; L A Madge; J Glöckner; J S Pober; S Ghosh
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia.

Authors:  Tim Niehues; Janine Reichenbach; Jennifer Neubert; Sonja Gudowius; Anne Puel; Gerd Horneff; Elke Lainka; Uta Dirksen; Horst Schroten; Rainer Döffinger; Jean Laurent Casanova; Volker Wahn
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

10.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more
  25 in total

1.  Correlating interleukin-12 stimulated interferon-γ production and the absence of ectodermal dysplasia and anhidrosis (EDA) in patients with mutations in NF-κB essential modulator (NEMO).

Authors:  Margje H Haverkamp; Beatriz E Marciano; David M Frucht; Ashish Jain; Esther van de Vosse; Steven M Holland
Journal:  J Clin Immunol       Date:  2014-02-28       Impact factor: 8.317

2.  Successful hematopoietic cell transplantation in patients with unique NF-κB essential modulator (NEMO) mutations.

Authors:  J K Abbott; R R Quinones; M T de la Morena; E W Gelfand
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

3.  NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus.

Authors:  Magali Audry; Michael Ciancanelli; Kun Yang; Aurelie Cobat; Huey-Hsuan Chang; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Tim Niehues; Janine Reichenbach; Xiao-Xia Li; Alain Israel; Laurent Abel; Jean-Laurent Casanova; Shen-Ying Zhang; Emmanuelle Jouanguy; Anne Puel
Journal:  J Allergy Clin Immunol       Date:  2011-07-01       Impact factor: 10.793

Review 4.  Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency.

Authors:  Capucine Picard; Jean-Laurent Casanova; Anne Puel
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  Genetic Susceptibility to Fungal Infections in Humans.

Authors:  Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2011-12-15

6.  Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection.

Authors:  Cullen M Dutmer; Edwin J Asturias; Christiana Smith; Megan K Dishop; D Scott Schmid; William J Bellini; Irit Tirosh; Yu Nee Lee; Luigi D Notarangelo; Erwin W Gelfand
Journal:  J Clin Immunol       Date:  2015-10-29       Impact factor: 8.317

7.  Fungal immunology in clinical practice: Magical realism or practical reality?

Authors:  Christina C Chang; Stuart M Levitz
Journal:  Med Mycol       Date:  2019-06-01       Impact factor: 4.076

Review 8.  The genetics of macrophage activation syndrome.

Authors:  Grant S Schulert; Randy Q Cron
Journal:  Genes Immun       Date:  2020-04-15       Impact factor: 2.676

Review 9.  Advances in basic and clinical immunology in 2008.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

Review 10.  A genetic perspective on granulomatous diseases with an emphasis on mycobacterial infections.

Authors:  Un-In Wu; Steven M Holland
Journal:  Semin Immunopathol       Date:  2016-01-05       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.